guest ::
| Home > Publications Database > [18F]GE-180-PET and Post Mortem Marker Characteristics of Long-Term High-Fat-Diet-Induced Chronic Neuroinflammation in Mice. > print |
| Home > Publications Database > [18F]GE-180-PET and Post Mortem Marker Characteristics of Long-Term High-Fat-Diet-Induced Chronic Neuroinflammation in Mice. > print |
| 001 | 258254 | ||
| 005 | 20231120155347.0 | ||
| 024 | 7 | _ | |a 10.3390/biom13050769 |2 doi |
| 024 | 7 | _ | |a pmid:37238638 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC10216137 |2 pmc |
| 037 | _ | _ | |a DZNE-2023-00600 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Müller, Luisa |0 0000-0001-7942-3273 |b 0 |
| 245 | _ | _ | |a [18F]GE-180-PET and Post Mortem Marker Characteristics of Long-Term High-Fat-Diet-Induced Chronic Neuroinflammation in Mice. |
| 260 | _ | _ | |a Basel |c 2023 |b MDPI |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1686818065_19488 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Obesity is characterized by immoderate fat accumulation leading to an elevated risk of neurodegenerative disorders, along with a host of metabolic disturbances. Chronic neuroinflammation is a main factor linking obesity and the propensity for neurodegenerative disorders. To determine the cerebrometabolic effects of diet-induced obesity (DIO) in female mice fed a long-term (24 weeks) high-fat diet (HFD, 60% fat) compared to a group on a control diet (CD, 20% fat), we used in vivo PET imaging with the radiotracer [18F]FDG as a marker for brain glucose metabolism. In addition, we determined the effects of DIO on cerebral neuroinflammation using translocator protein 18 kDa (TSPO)-sensitive PET imaging with [18F]GE-180. Finally, we performed complementary post mortem histological and biochemical analyses of TSPO and further microglial (Iba1, TMEM119) and astroglial (GFAP) markers as well as cerebral expression analyses of cytokines (e.g., Interleukin (IL)-1β). We showed the development of a peripheral DIO phenotype, characterized by increased body weight, visceral fat, free triglycerides and leptin in plasma, as well as increased fasted blood glucose levels. Furthermore, we found obesity-associated hypermetabolic changes in brain glucose metabolism in the HFD group. Our main findings with respect to neuroinflammation were that neither [18F]GE-180 PET nor histological analyses of brain samples seem fit to detect the predicted cerebral inflammation response, despite clear evidence of perturbed brain metabolism along with elevated IL-1β expression. These results could be interpreted as a metabolically activated state in brain-resident immune cells due to a long-term HFD. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a TSPO |2 Other |
| 650 | _ | 7 | |a [18F]FDG PET/CT |2 Other |
| 650 | _ | 7 | |a [18F]GE-180 PET/CT |2 Other |
| 650 | _ | 7 | |a diet-induced obesity |2 Other |
| 650 | _ | 7 | |a high-fat diet |2 Other |
| 650 | _ | 7 | |a neuroinflammation |2 Other |
| 650 | _ | 7 | |a GE-180 |2 NLM Chemicals |
| 650 | _ | 7 | |a Carrier Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Glucose |0 IY9XDZ35W2 |2 NLM Chemicals |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Diet, High-Fat: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Neuroinflammatory Diseases |2 MeSH |
| 650 | _ | 2 | |a Obesity: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Obesity: metabolism |2 MeSH |
| 650 | _ | 2 | |a Carrier Proteins |2 MeSH |
| 650 | _ | 2 | |a Neurodegenerative Diseases |2 MeSH |
| 650 | _ | 2 | |a Glucose |2 MeSH |
| 650 | _ | 2 | |a Positron-Emission Tomography: methods |2 MeSH |
| 650 | _ | 2 | |a Mice, Inbred C57BL |2 MeSH |
| 700 | 1 | _ | |a Power Guerra, Nicole |0 0000-0001-6036-7574 |b 1 |
| 700 | 1 | _ | |a Schildt, Anna |b 2 |
| 700 | 1 | _ | |a Lindner, Tobias |0 0000-0001-7826-3132 |b 3 |
| 700 | 1 | _ | |a Stenzel, Jan |b 4 |
| 700 | 1 | _ | |a Behrangi, Newshan |b 5 |
| 700 | 1 | _ | |a Bergner, Carina |b 6 |
| 700 | 1 | _ | |a Alberts, Teresa |b 7 |
| 700 | 1 | _ | |a Bühler, Daniel |b 8 |
| 700 | 1 | _ | |a Kurth, Jens |0 0000-0001-6864-4513 |b 9 |
| 700 | 1 | _ | |a Krause, Bernd Joachim |b 10 |
| 700 | 1 | _ | |a Janowitz, Deborah |b 11 |
| 700 | 1 | _ | |a Teipel, Stefan |0 P:(DE-2719)2000026 |b 12 |u dzne |
| 700 | 1 | _ | |a Vollmar, Brigitte |b 13 |
| 700 | 1 | _ | |a Kuhla, Angela |b 14 |
| 770 | _ | _ | |a Novel Imaging Biomarkers for Brain PET Imaging |
| 773 | _ | _ | |a 10.3390/biom13050769 |g Vol. 13, no. 5, p. 769 - |0 PERI:(DE-600)2701262-1 |n 5 |p 769 |t Biomolecules |v 13 |y 2023 |x 2218-273X |
| 856 | 4 | _ | |u https://pub.dzne.de/record/258254/files/DZNE-2023-00600%20SUP.zip |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/258254/files/DZNE-2023-00600.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/258254/files/DZNE-2023-00600.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:258254 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2000026 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-22 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-22 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2022-11-22 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2022-11-22 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-04-12T14:57:05Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-04-12T14:57:05Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-04-12T14:57:05Z |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BIOMOLECULES : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-26 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b BIOMOLECULES : 2022 |d 2023-10-26 |
| 920 | 1 | _ | |0 I:(DE-2719)1510100 |k AG Teipel |l Clinical Dementia Research Rostock /Greifswald |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1510100 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|